Research programme: antibody therapeutics - Sutro Biopharma

Drug Profile

Research programme: antibody therapeutics - Sutro Biopharma

Alternative Names: DBCO-Alexa647-conjugated SP7219; SP 7219; SP 7675; SP 7676; STRO-002

Latest Information Update: 30 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sutro Biopharma
  • Class Antibodies; Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action Folate receptor 1 antagonists; Invariant chain inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Endometrial cancer; Ovarian cancer

Most Recent Events

  • 12 Sep 2018 Sutro Biopharma announces intention to file an IND application for STR 002 for Cancer, in the fourth quarter of 2018
  • 26 Jul 2018 Sutro Biopharma plans a phase I trial for STRO 002 for Ovarian and endometrial cancer by early 2019
  • 21 Apr 2018 Pharmacodynamics data from preclinical studies in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top